{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T02:25:21Z","timestamp":1762050321255,"version":"3.40.5"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["FB is senior research associate"],"award-info":[{"award-number":["FB is senior research associate"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of measurable residual disease (MRD) on cord blood transplantation (CBT) outcomes has remained debated. To address this issue, we assessed the impact of measurable MRD at CBT on outcomes in large cohort of patients with acute leukemia. Inclusion criteria included adult patients with acute myeloid (AML) or acute lymphoblastic leukemia (ALL), CBT as first allo\u2010HCT in first or second complete remission (CR) at transplantation, and known MRD status at the time of CBT. Data from 506 patients were included in the analysis. Among them, 317 patients had AML and 189 had ALL. Positive MRD was reported in 169 (33%) patients while the remaining 337 patients were MRD negative at CBT. At 2\u2009years, relapse incidence was 18% in patients with MRD negativity vs 33% in those with MRD positivity at transplantation (<jats:italic>P<\/jats:italic> &lt;\u2009.001). Two\u2010year leukemia\u2010free survival (LFS) and overall survival (OS) were 57% and 60%, respectively, in MRD negative patients, vs 38% (<jats:italic>P<\/jats:italic> &lt;\u2009.001) and 48% (<jats:italic>P<\/jats:italic> =\u2009.004), respectively, in those with MRD positivity. There was no interaction between the impact of MRD on OS and LFS and diagnosis (ie, ALL vs AML), single or double CBT, and reduced\u2010intensity or myeloablative conditioning. On multivariate analysis, MRD positivity was associated with a higher risk of relapse (HR = 1.8, <jats:italic>P<\/jats:italic> =\u2009.003), comparable non\u2010relapse mortality (<jats:italic>P<\/jats:italic> =\u2009.44), worse LFS (HR = 1.4, <jats:italic>P<\/jats:italic> =\u2009.008) and a trend towards worse OS (HR = 1.3, <jats:italic>P<\/jats:italic> =\u2009.065). In conclusion, these data suggest that novel strategies that are aiming to achieve MRD negativity at CBT are needed for leukemic patients with positive MRD pre\u2010CBT.<\/jats:p>","DOI":"10.1002\/ajh.25879","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T16:45:56Z","timestamp":1590425156000},"page":"1057-1065","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of detectable measurable residual disease on umbilical cord blood transplantation"],"prefix":"10.1002","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-3812","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"first","affiliation":[{"name":"Laboratory of Hematology, GIGA\u2010I3 University of Liege and CHU of Li\u00e8ge  Liege Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[{"name":"EBMT Paris Study Office\/CEREST\u2010TC  Paris France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire APHP, H\u00f4pital Saint Antoine  Paris France"},{"name":"Centre de Recherche Saint\u2010Antoine (CRSA) INSERM  Paris France"},{"name":"Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7261-2765","authenticated-orcid":false,"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Ospedale San Raffaele s.r.l., Haematology and BMT  Milan Italy"},{"name":"Eurocord, Hospital Saint Louis, AP\u2010HP, and IUH University Paris VII, France; Monacord, Centre Scientifique de Monaco  Monaco Monaco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Sierra","sequence":"additional","affiliation":[{"name":"Department of Hematology Hospital Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Haematology Bristol Haematology Oncology Centre, University Hospital Bristol  Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re\u2010Wallet","sequence":"additional","affiliation":[{"name":"Service Hematologie Centre Hospitalier Lyon Sud  Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Potter","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital Leukaemia Myeloma Units  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6024","authenticated-orcid":false,"given":"Josep\u2010Maria","family":"Ribera","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology ICO\u2010Hospital Universitari Germans Trias i Pujol Josep Carreras Research Institute  Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Deconinck","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Hopital Jean Minjoz  Besancon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology University of Milan and Azienda Socio Sanitaria Territoriale, Papa Giovanni XXIII  Bergamo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre\u2010Simon","family":"Rohrlich","sequence":"additional","affiliation":[{"name":"CHU Nice \u2010 H\u00f4pital de l'ARCHET I, Hematologie Clinique  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"de Revel","sequence":"additional","affiliation":[{"name":"Department of Hematology H\u00f4pital Am\u00e9ricain  Clamart France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane","family":"Gluckman","sequence":"additional","affiliation":[{"name":"Eurocord, Hospital Saint Louis, AP\u2010HP, and IUH University Paris VII, France; Monacord, Centre Scientifique de Monaco  Monaco Monaco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"EBMT Paris Study Office\/CEREST\u2010TC  Paris France"},{"name":"Division of Hematology and Bone Marrow Transplantation The Chaim Sheba Medical Center, Tel\u2010Hashomer  Ramat\u2010Gan Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"EBMT Paris Study Office\/CEREST\u2010TC  Paris France"},{"name":"Service d'H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire APHP, H\u00f4pital Saint Antoine  Paris France"},{"name":"Centre de Recherche Saint\u2010Antoine (CRSA) INSERM  Paris France"},{"name":"Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_10_2_1","DOI":"10.3324\/haematol.2019.221333"},{"doi-asserted-by":"publisher","key":"e_1_2_10_3_1","DOI":"10.1038\/leu.2016.183"},{"doi-asserted-by":"publisher","key":"e_1_2_10_4_1","DOI":"10.1182\/blood-2014-09-599894"},{"doi-asserted-by":"publisher","key":"e_1_2_10_5_1","DOI":"10.1038\/s41409-018-0373-4"},{"doi-asserted-by":"publisher","key":"e_1_2_10_6_1","DOI":"10.1002\/cncr.30130"},{"doi-asserted-by":"publisher","key":"e_1_2_10_7_1","DOI":"10.2991\/chi.d.190316.001"},{"doi-asserted-by":"publisher","key":"e_1_2_10_8_1","DOI":"10.1002\/ajh.25795"},{"doi-asserted-by":"publisher","key":"e_1_2_10_9_1","DOI":"10.1002\/ajh.25355"},{"doi-asserted-by":"publisher","key":"e_1_2_10_10_1","DOI":"10.1038\/leu.2012.135"},{"doi-asserted-by":"publisher","key":"e_1_2_10_11_1","DOI":"10.1186\/s13045-017-0497-9"},{"doi-asserted-by":"publisher","key":"e_1_2_10_12_1","DOI":"10.3389\/fimmu.2017.00496"},{"doi-asserted-by":"publisher","key":"e_1_2_10_13_1","DOI":"10.1038\/bmt.2017.34"},{"doi-asserted-by":"publisher","key":"e_1_2_10_14_1","DOI":"10.1182\/blood-2004-07-2717"},{"doi-asserted-by":"publisher","key":"e_1_2_10_15_1","DOI":"10.1182\/blood-2013-02-453175"},{"doi-asserted-by":"publisher","key":"e_1_2_10_16_1","DOI":"10.1056\/NEJMoa1602074"},{"doi-asserted-by":"publisher","key":"e_1_2_10_17_1","DOI":"10.1111\/joim.12870"},{"doi-asserted-by":"publisher","key":"e_1_2_10_18_1","DOI":"10.1158\/1078-0432.CCR-17-3622"},{"doi-asserted-by":"publisher","key":"e_1_2_10_19_1","DOI":"10.1111\/joim.12696"},{"doi-asserted-by":"publisher","key":"e_1_2_10_20_1","DOI":"10.1038\/leu.2016.46"},{"doi-asserted-by":"publisher","key":"e_1_2_10_21_1","DOI":"10.1182\/blood-2018-02-829911"},{"doi-asserted-by":"publisher","key":"e_1_2_10_22_1","DOI":"10.1186\/s13045-019-0790-x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_23_1","DOI":"10.1002\/ajh.25647"},{"doi-asserted-by":"publisher","key":"e_1_2_10_24_1","DOI":"10.1002\/ajh.25514"},{"doi-asserted-by":"publisher","key":"e_1_2_10_25_1","DOI":"10.1002\/ajh.25417"},{"doi-asserted-by":"publisher","key":"e_1_2_10_26_1","DOI":"10.1002\/ajh.25338"},{"doi-asserted-by":"publisher","key":"e_1_2_10_27_1","DOI":"10.1038\/s41375-019-0527-4"},{"doi-asserted-by":"publisher","key":"e_1_2_10_28_1","DOI":"10.1002\/ajh.25211"},{"doi-asserted-by":"publisher","key":"e_1_2_10_29_1","DOI":"10.1111\/bjh.15540"},{"doi-asserted-by":"publisher","key":"e_1_2_10_30_1","DOI":"10.18632\/oncotarget.9599"},{"doi-asserted-by":"publisher","key":"e_1_2_10_31_1","DOI":"10.1097\/00007890-197410000-00001"},{"doi-asserted-by":"publisher","key":"e_1_2_10_32_1","DOI":"10.1038\/bmt.2015.305"},{"doi-asserted-by":"publisher","key":"e_1_2_10_33_1","DOI":"10.1182\/blood-2009-11-254441"},{"doi-asserted-by":"publisher","key":"e_1_2_10_34_1","DOI":"10.1111\/bjh.12970"},{"doi-asserted-by":"publisher","key":"e_1_2_10_35_1","DOI":"10.1182\/blood-2009-05-220525"},{"doi-asserted-by":"publisher","key":"e_1_2_10_36_1","DOI":"10.1182\/blood-2015-11-675504"},{"doi-asserted-by":"publisher","key":"e_1_2_10_37_1","DOI":"10.1182\/blood-2016-06-718619"},{"issue":"1","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-015-0207-4","article-title":"Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft\u2010versus\u2010host disease and lower survival in male patients transplanted with female unrelated cord blood\u2010a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation","volume":"8","author":"Baron F","year":"2015","journal-title":"J Hematol Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_10_39_1","DOI":"10.1038\/leu.2013.259"},{"doi-asserted-by":"publisher","key":"e_1_2_10_40_1","DOI":"10.1038\/bmt.2014.216"},{"doi-asserted-by":"publisher","key":"e_1_2_10_41_1","DOI":"10.1182\/blood-2014-09-599241"},{"doi-asserted-by":"publisher","key":"e_1_2_10_42_1","DOI":"10.3324\/haematol.2018.211615"},{"doi-asserted-by":"publisher","key":"e_1_2_10_43_1","DOI":"10.1038\/s41409-018-0286-2"},{"issue":"5","key":"e_1_2_10_44_1","first-page":"e1314425","article-title":"Azacytidine prevents experimental xenogeneic graft\u2010versus\u2010host disease without abrogating graft\u2010versus\u2010leukemia effects","volume":"6","author":"Ehx G","year":"2017","journal-title":"Onco Targets Ther"},{"doi-asserted-by":"publisher","key":"e_1_2_10_45_1","DOI":"10.1016\/j.bbmt.2015.09.004"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25879","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T18:53:54Z","timestamp":1693940034000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/ajh.25879"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25879","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"type":"print","value":"0361-8609"},{"type":"electronic","value":"1096-8652"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"2020-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}